Hypocretin antagonists in insomnia treatment and beyond

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1476-1482

  Ruoff, Chad ^a   Cao, Michelle ^a   Guilleminault, Christian ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Almorexant; Cataplexy; Hypocretin; Insomnia; MK 4305; Narcolepsy; Orexin; Sleep

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ACETYLSALICYLIC ACID; ALMOREXANT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; MELATONIN RECEPTOR; NEUROLEPTIC AGENT; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PLACEBO; SB 649868; SUVOREXANT; ZOLPIDEM;

ADDICTION; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; CATAPLEXY; COGNITION; COORDINATION; CREATINE KINASE BLOOD LEVEL; DIPLOPIA; DIZZINESS; DROWSINESS; ENERGY EXPENDITURE; FATIGUE; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REWARD; SEDATION; SIDE EFFECT; SLEEP WAKING CYCLE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIVID DREAM;

ANIMALS; DRUG DESIGN; HUMANS; HYPNOTICS AND SEDATIVES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; WAKEFULNESS;

EID: 84856281837     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197089     Document Type: Article

References (81)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus- specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95(1): 322-7.
2. Gautvik KM, de Lecea L, Gautvik VT, et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sci USA 1996; 93(16): 8733-8.
3. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998; 92(4): 573-85.
4. Tang J, Chen J, Ramanjaneya M, Punn A, Conner AC, Randeva HS. The signalling profile of recombinant human orexin-2 receptor. Cell Signal 2008; 20(9): 1651-61.
5. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27(3): 469-74.
6. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18(23): 9996-10015.
7. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435(1): 6-25.
8. Arihara Z, Takahashi K, Murakami O, et al. Immunoreactive orexin-A in human plasma. Peptides 2001; 22(1): 139-42.
9. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355(9197): 39-40.
10. Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. Prepro- orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 2001; 142(8): 3324-31.
11. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50(2 Suppl 1): S16-22.
12. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005; 65(8): 1184-8.
13. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; 41(6): 708-11.
14. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011; 43(1): 66-71.
15. Miyagawa T, Kawashima M, Nishida N, et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008; 40(11): 1324-8.
16. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6(9): 991-7.
17. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59(10): 1553-62.
18. Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994; 17(8 Suppl): S60-7.
19. Matsuki K, Grumet FC, Lin X, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992; 339(8800): 1052.
20. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98(3): 365-76.
21. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98(4): 437-51.
22. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38(5): 715-30.
23. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000; 12(2): 726-30.
24. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004; 101(13): 4649-54.
25. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001; 98(17): 9965-70.
26. Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002; 290(4): 1237-45.
27. Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009; 330(1): 142-51.
28. Hondo M, Nagai K, Ohno K, et al. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol (Oxf) 2010; 198(3): 287-94.
29. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005; 25(28): 6716-20.
30. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24(12): 726-31.
31. Sherin JE, Shiromani PJ, McCarley RW, Saper CB. Activation of ventrolateral preoptic neurons during sleep. Science 1996; 271(5246): 216-9.
32. Szymusiak R, Alam N, Steininger TL, McGinty D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 1998; 803(1-2): 178-88.
33. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008; 29(1): 70-87.
34. Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000; 23(8): 359-65.
35. Li Y, Gao XB, Sakurai T, van den Pol AN. Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002; 36(6): 1169-81.
36. Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci 2004; 24(32): 7159-66.
37. el Mansari M, Sakai K, Jouvet M. Unitary characteristics of presumptive cholinergic tegmental neurons during the sleep-waking cycle in freely moving cats. Exp Brain Res 1989; 76(3): 519-29.
38. Arrigoni E, Mochizuki T, Scammell TE. Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 2010; 198(3): 223-35.
39. Eggermann E, Serafin M, Bayer L, et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001; 108(2): 177-81.
40. Fadel J, Pasumarthi R, Reznikov LR. Stimulation of cortical acetylcholine release by orexin A. Neuroscience 2005; 130(2): 541-7.
41. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28(9): 1049-57.
42. Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat 2010; 20(3): 307-24.
43. A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population. 2010; Available at: http://clinicaltrials.gov/ct2/show/NCT00534872?term=SB+%E2%80%93+649868&rank=1. Accessed 02/14, 2011.
44. Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthyvolunteers. 2009; Available at: http://clinicaltrials.gov/ct2/show/NCT01030939?term=SB+%E2%80%93+649868&rank=4. Accessed 02/14, 2011.
45. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)- 7-methyl-1,4-diazepan-1-yl] [5-methy l-2-(2H-1,2,3-triazol- 2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010; 53(14): 5320-32.
46. Results Presented from Phase IIb Clinical Study of Merck's Investigational Insomnia Therapy MK-4305. 2010; Available at: http://www.merck.com/newsroom/news-release-archive/research-anddevelopment/2010_0609.html. Accessed 02/14, 2011.
47. Safety and Efficacy Study in Primary Insomnia Patients- Study A (4305-028). 2011; Available at: http://clinicaltrials.gov/ct2/show/NCT01097616?term=MK-4305&rank=1. Accessed 02/14, 2011.
48. Safety and Efficacy Study in Primary Insomnia Patients-Study B (4305-029). 2011; Available at: http://clinicaltrials.gov/ct2/show/NCT01097629?term=MK-4305&rank=2. Accessed 02/14, 2011.
49. A Long Term Safety Study of MK4305 in Patients With Primary Insomnia (4305-009). 2011; Available at: http://clinicaltrials.gov/ct2/show/NCT01021813?term=MK-4305&rank=4. Accessed 02/14, 2011.
50. Pharmacokinetics of MK4305 in Patients With Hepatic Insufficiency. 2010; Available at: http://clinicaltrials.gov/ct2/show/NCT01043926?term=MK-4305&rank=7. Accessed 02/14, 2011.
51. Pharmacokinetics of MK4305 in Patients With Impaired Renal Function. 2010; Available at: http://clinicaltrials.gov/ct2/show/NCT01059851?term=MK-4305&rank=3. Accessed 02/14, 2011.
52. [Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032). 2011; Available at: http://clinicaltrials.gov/ct2/show/NCT01293006?term=MK-4305&rank=5. Accessed 02/14, 2011.
53. Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010; 87(5): 593-600.
54. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13(2): 150-5.
55. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001; 14(7): 1075-81.
56. ACT-078573 in Elderly Subjects With Chronic Primary Insomnia. 2010; Available at: http://clinicaltrials.gov/ct2/show/NCT00606593?term=almorexant&rank=4. Accessed 02/13, 2011.
57. Investigational dual orexin receptor antagonist almorexant meets primary endpoint in two-week phase III study in patients suffering from primary insomnia. 2011; Available at: http://www1.actelion.com/en/our-company/news-andevents/index.page?newsId=1365361. Accessed 02/13, 2011.
58. Actelion and GSK Discontinue Clinical Development of Almorexant. 2011; Available at: http://www1.actelion.com/en/journalists/news-archive.page?newsId=1483135. Accessed 02/13, 2011.
59. Young JK, Wu M, Manaye KF, et al. Orexin stimulates breathing via medullary and spinal pathways. J Appl Physiol 2005; 98(4): 1387-95.
60. Han F, Mignot E, Wei YC, et al. Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J 2010; 36(3): 577-83.
61. Zhang W, Fukuda Y, Kuwaki T. Respiratory and cardiovascular actions of orexin-A in mice. Neurosci Lett 2005 Sep 9; 385(2): 131-6.
62. Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T. Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol 2007; 102(1): 241-8.
63. Li A, Nattie E. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 2010; 588(Pt 15): 2935-44.
64. Williams RH, Jensen LT, Verkhratsky A, Fugger L, Burdakov D. Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci USA 2007; 104(25): 10685-90.
65. Sunanaga J, Deng BS, Zhang W, Kanmura Y, Kuwaki T. CO2 activates orexin-containing neurons in mice. Respir Physiol Neurobiol 2009; 166(3): 184-6.
66. Teske JA, Billington CJ, Kotz CM. Hypocretin/orexin and energy expenditure. Acta Physiol (Oxf) 2010; 198(3): 303-12.
67. Willie JT, Takahira H, Shibahara M, et al. Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice. J Mol Neurosci 2011; 43(2): 155-61.
68. Benca RM. Narcolepsy and excessive daytime sleepiness: diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry 2007; 68 Suppl 13: 5-8.
69. LeSage MG, Perry JL, Kotz CM, Shelley D, Corrigall WA. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berl) 2010; 209(2): 203-12.
70. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006; 49(4): 589-601.
71. Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin-orexin system regulates cocaine selfadministration via actions on the mesolimbic dopamine system. Eur J Neurosci 2010; 31(2): 336-48.
72. Boutrel B, Kenny PJ, Specio SE, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 2005; 102(52): 19168-73.
73. Narita M, Nagumo Y, Hashimoto S, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 2006; 26(2): 398-405.
74. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased bodymass index in patients with narcolepsy. Lancet 2000; 355(9211): 1274-5.
75. Hara J, Yanagisawa M, Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 2005; 380(3): 239-42.
76. Haynes AC, Jackson B, Chapman H, et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000; 96(1-2): 45-51.
77. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003; 38(5): 701-13.
78. Kuru M, Ueta Y, Serino R, et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 2000; 11(9): 1977-80.
79. Furuta M, Mitsushima D, Shinohara K, Kimura F, Funabashi T. Food availability affects orexin a/ hypocretin-1-induced inhibition of pulsatile luteinizing hormone secretion in female rats. Neuroendocrinology 2010; 91(1): 41-7.
80. Dietrich H, Jenck F. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) 2010; 212(2): 145-54.
81. Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck F. Differential Effects of the Dual Orexin Receptor Antagonist Almorexant and the GABA(A)-alpha1 Receptor Modulator Zolpidem, Alone or Combined with Ethanol, on Motor Performance in the Rat. Neuropsychopharmacology 2010 Dec 8.